目的观察苏沈九宝汤治疗支气管哮喘急性发作期的临床疗效和对Th1/Th2因子的影响。方法选取2022年2月至2023年5月于浙江中医药大学附属四省边际中医院诊治的98例支气管哮喘急性发作期患者,根据随机数字表法将其分为治疗组和对照组,每组...目的观察苏沈九宝汤治疗支气管哮喘急性发作期的临床疗效和对Th1/Th2因子的影响。方法选取2022年2月至2023年5月于浙江中医药大学附属四省边际中医院诊治的98例支气管哮喘急性发作期患者,根据随机数字表法将其分为治疗组和对照组,每组各49例。对照组患者给予吸氧、雾化等常规治疗,治疗组患者在对照组基础上加用苏沈九宝汤。比较两组患者的临床疗效、中医证候积分、肺功能指标[第一秒用力呼气量(forced expiratory volume in first second,FEV1)、呼气流量峰值(peak expiratory flow,PEF)]和实验室指标[白细胞介素(interleukin,IL)-4、IL-13、γ干扰素(interferon-γ,IFN-γ)、免疫球蛋白E(immunoglobulin E,IgE)]。结果治疗组患者的总有效率显著高于对照组(χ^(2)=9.287,P=0.010);治疗后,两组患者的中医证候积分、血清IL-4、IL-13、IgE水平均显著低于本组治疗前,FEV_(1)、PEF、IFN-γ水平均显著高于本组治疗前(P<0.05),治疗组患者的中医证候积分、血清IL-4、IL-13、IgE水平均显著低于对照组,FEV1、PEF、IFN-γ水平均显著高于对照组(P<0.05)。结论苏沈九宝汤治疗支气管哮喘急性发作,可显著提高临床疗效,降低患者的炎症因子水平,改善肺功能。展开更多
Objective: Cancer immunotherapy has made remarkable advances in recent years, but its effectiveness in treating gastric cancer is often limited by the complexity of the tumor microenvironment and the lack of effective...Objective: Cancer immunotherapy has made remarkable advances in recent years, but its effectiveness in treating gastric cancer is often limited by the complexity of the tumor microenvironment and the lack of effective biomarkers. This study aimed to identify effective biomarkers for immunotherapy treatment by characterizing the tumor microenvironment.Methods: We retrieved the RNA-seq data from gastric cancer patients treated with the programmed death 1(PD-1) blockade pembrolizumab. Differentially expressed genes associated with clinical outcomes were identified and further analyzed using gene ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway analysis. Gene signature scores were calculated by single sample Gene Set Enrichment Analysis(ssGSEA). The infiltration levels of immune cells were quantified using the xCell website. Cell type enrichment analysis was performed to compare treatment response and non-response groups, and regression analysis was used to investigate the relationship between interferon gamma(IFNγ) immune response and immune cell infiltration. Biomarkers were identified using least absolute shrinkage and selection operator(LASSO) analysis.Results: Compared to normal tissues, cytokine activity and interleukin-6 production were highly activated in gastric tumors. Responders to pembrolizumab showed significantly up-regulated expression of IFNγ responserelated genes. Cell type enrichment analysis revealed that Th1 cells were significantly enriched in the tumor microenvironment of responders. Regression analysis indicated that Th1 cells induced IFNγ response more efficiently than other cell types. Using signatures of Th1 cells, stromal cells and IFNγ response, a set of eight genes were identified that effectively predicted the efficacy of immunotherapy treatment and patient prognosis.Conclusions: Th1 cells promote therapeutic efficacy of PD-1 blockade by promoting IFNγ immune response in gastric cancer. The identified biomarkers have the potential to improve the effectiveness of immunotherapy treatment for gastric cancer patients.展开更多
Introduction:Allergen-specific CD4+T cells play a central role in autoimmune disorders,allergies and asthma,with Th2-type immunity being the typical functional response of CD4+T cells.This study aimed to investigate t...Introduction:Allergen-specific CD4+T cells play a central role in autoimmune disorders,allergies and asthma,with Th2-type immunity being the typical functional response of CD4+T cells.This study aimed to investigate the role of MBD2 in regulating Th2 cell differentiation.Methods:Splenic mononuclear cells were extracted from C57BL/6 mice,and CD4+T cells were isolated using magnetic beads and confirmed through flow cytometry.Lentivirus was employed to construct MBD2-silenced CD4+T cells.In vitro experiments were performed to treat splenogenic mononuclear cells and CD4+T cells with Ovalbumin(OVA),and Th2 cell ratios and IL-4 levels were assessed using flow cytometry and ELISA.Results:The purity of the isolated CD4+T cells was 95.73%,confirming successful isolation of primary CD4+T cells.Compared to the control group,the Th2 cell ratio exhibited an increase in the Th2-induced group.Treatment with 5-Aza(concentrations,1-100μM)promoted Th2 cell differentiation and increased IL-4 levels.Notably,when combined with Th2 induction and 10μM 5-Aza treatment,silencing MBD2 further amplified Th2 cell ratios and elevated IL-4 levels in cell supernatants.Furthermore,OVA(concentration,200μg/mL)induced the differentiation of CD4+T cells into Th2 cells and increased IL-4 secretion.Interestingly,silencing MBD2 significantly increased the Th2 cell ratio and IL-4 levels in OVA-treated CD4+T cells.Conclusion:In summary,OVA promoted CD4+T cell differentiation into Th2 cells and enhanced IL-4 levels.MBD2 was identified as a mediator of Th2 cell differentiation in splenic-derived CD4+T cells,influenced by OVA or 5-Aza treatment.展开更多
文摘目的观察苏沈九宝汤治疗支气管哮喘急性发作期的临床疗效和对Th1/Th2因子的影响。方法选取2022年2月至2023年5月于浙江中医药大学附属四省边际中医院诊治的98例支气管哮喘急性发作期患者,根据随机数字表法将其分为治疗组和对照组,每组各49例。对照组患者给予吸氧、雾化等常规治疗,治疗组患者在对照组基础上加用苏沈九宝汤。比较两组患者的临床疗效、中医证候积分、肺功能指标[第一秒用力呼气量(forced expiratory volume in first second,FEV1)、呼气流量峰值(peak expiratory flow,PEF)]和实验室指标[白细胞介素(interleukin,IL)-4、IL-13、γ干扰素(interferon-γ,IFN-γ)、免疫球蛋白E(immunoglobulin E,IgE)]。结果治疗组患者的总有效率显著高于对照组(χ^(2)=9.287,P=0.010);治疗后,两组患者的中医证候积分、血清IL-4、IL-13、IgE水平均显著低于本组治疗前,FEV_(1)、PEF、IFN-γ水平均显著高于本组治疗前(P<0.05),治疗组患者的中医证候积分、血清IL-4、IL-13、IgE水平均显著低于对照组,FEV1、PEF、IFN-γ水平均显著高于对照组(P<0.05)。结论苏沈九宝汤治疗支气管哮喘急性发作,可显著提高临床疗效,降低患者的炎症因子水平,改善肺功能。
基金financially supported by the National Natural Science Foundation of China (No. 82030079, 82341005, 81972656 and 82173035)the National Science and Technology Major Project of China (No. 2022YFC3400 901)Sino-Russian Math Center in PKU。
文摘Objective: Cancer immunotherapy has made remarkable advances in recent years, but its effectiveness in treating gastric cancer is often limited by the complexity of the tumor microenvironment and the lack of effective biomarkers. This study aimed to identify effective biomarkers for immunotherapy treatment by characterizing the tumor microenvironment.Methods: We retrieved the RNA-seq data from gastric cancer patients treated with the programmed death 1(PD-1) blockade pembrolizumab. Differentially expressed genes associated with clinical outcomes were identified and further analyzed using gene ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway analysis. Gene signature scores were calculated by single sample Gene Set Enrichment Analysis(ssGSEA). The infiltration levels of immune cells were quantified using the xCell website. Cell type enrichment analysis was performed to compare treatment response and non-response groups, and regression analysis was used to investigate the relationship between interferon gamma(IFNγ) immune response and immune cell infiltration. Biomarkers were identified using least absolute shrinkage and selection operator(LASSO) analysis.Results: Compared to normal tissues, cytokine activity and interleukin-6 production were highly activated in gastric tumors. Responders to pembrolizumab showed significantly up-regulated expression of IFNγ responserelated genes. Cell type enrichment analysis revealed that Th1 cells were significantly enriched in the tumor microenvironment of responders. Regression analysis indicated that Th1 cells induced IFNγ response more efficiently than other cell types. Using signatures of Th1 cells, stromal cells and IFNγ response, a set of eight genes were identified that effectively predicted the efficacy of immunotherapy treatment and patient prognosis.Conclusions: Th1 cells promote therapeutic efficacy of PD-1 blockade by promoting IFNγ immune response in gastric cancer. The identified biomarkers have the potential to improve the effectiveness of immunotherapy treatment for gastric cancer patients.
基金supported by grants from the National Natural Science Foundation of China(Nos.81760009 and 81560007).
文摘Introduction:Allergen-specific CD4+T cells play a central role in autoimmune disorders,allergies and asthma,with Th2-type immunity being the typical functional response of CD4+T cells.This study aimed to investigate the role of MBD2 in regulating Th2 cell differentiation.Methods:Splenic mononuclear cells were extracted from C57BL/6 mice,and CD4+T cells were isolated using magnetic beads and confirmed through flow cytometry.Lentivirus was employed to construct MBD2-silenced CD4+T cells.In vitro experiments were performed to treat splenogenic mononuclear cells and CD4+T cells with Ovalbumin(OVA),and Th2 cell ratios and IL-4 levels were assessed using flow cytometry and ELISA.Results:The purity of the isolated CD4+T cells was 95.73%,confirming successful isolation of primary CD4+T cells.Compared to the control group,the Th2 cell ratio exhibited an increase in the Th2-induced group.Treatment with 5-Aza(concentrations,1-100μM)promoted Th2 cell differentiation and increased IL-4 levels.Notably,when combined with Th2 induction and 10μM 5-Aza treatment,silencing MBD2 further amplified Th2 cell ratios and elevated IL-4 levels in cell supernatants.Furthermore,OVA(concentration,200μg/mL)induced the differentiation of CD4+T cells into Th2 cells and increased IL-4 secretion.Interestingly,silencing MBD2 significantly increased the Th2 cell ratio and IL-4 levels in OVA-treated CD4+T cells.Conclusion:In summary,OVA promoted CD4+T cell differentiation into Th2 cells and enhanced IL-4 levels.MBD2 was identified as a mediator of Th2 cell differentiation in splenic-derived CD4+T cells,influenced by OVA or 5-Aza treatment.
